So we randomized 202 patients referred for salvage radiotherapy because of a rising PSA between either radiotherapy with six months of conventional ADT versus six months of apalutamide monotherapy. We looked at PROMs, so we collected FACT-B, EPIC-26 and EORTC PR25 and C30 questionnaires at 3, 6 and 9 months after treatment initiation. And we found that apalutamide monotherapy significantly spared erectile function, so sexual function, in those patients with also general health-related quality of life...
So we randomized 202 patients referred for salvage radiotherapy because of a rising PSA between either radiotherapy with six months of conventional ADT versus six months of apalutamide monotherapy. We looked at PROMs, so we collected FACT-B, EPIC-26 and EORTC PR25 and C30 questionnaires at 3, 6 and 9 months after treatment initiation. And we found that apalutamide monotherapy significantly spared erectile function, so sexual function, in those patients with also general health-related quality of life. And it did so without hampering PSA responses. So the oncological outcome was identical.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
